TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from EMvision Medical Devices Ltd. ( (AU:EMV) ) is now available.
EMVision Medical Devices Ltd has made significant progress in its Pivotal (Validation) Trial for the emu™ brain scanner, aimed at supporting regulatory submission and market entry in the US and other global markets. The company has expanded its clinical footprint in the US with the activation of UCLA Health as a trial site, and recruitment is expected to accelerate. EMVision also received a $3 million grant to evaluate an expedited stroke care model in regional hospitals, highlighting the alignment of its mission with government priorities for equitable healthcare access. Additionally, the company raised $12 million through a placement, bolstering its financial position with cash reserves of $18.35 million as of September 2025.
The most recent analyst rating on (AU:EMV) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on EMvision Medical Devices Ltd. stock, see the AU:EMV Stock Forecast page.
More about EMvision Medical Devices Ltd.
EMVision Medical Devices Ltd is an Australian company specializing in the development and commercialization of innovative neurodiagnostic technology. The company focuses on creating portable, cost-effective, and non-ionizing brain scanners, including the bedside emu™ device and the ultra-lightweight First Responder device. EMVision targets acute stroke care and traumatic brain injury, addressing significant societal and health economic challenges by meeting the critical need for portable brain scanners to improve patient outcomes.
Average Trading Volume: 81,719
Technical Sentiment Signal: Sell
Current Market Cap: A$170M
Learn more about EMV stock on TipRanks’ Stock Analysis page.